Navigation Links
Palatin Technologies Announces Third Quarter Fiscal Year 2013 Results and Update on Development of Bremelanotide for Female Sexual Dysfunction
Date:5/14/2013

cessful NDA filing and furthering our discussions with potential collaboration partners."

Based upon the discussions with FDA, Palatin intends to finalize the protocols for the pivotal Phase 3 clinical studies and start screening patients later this year.

Quarter Ended March 31, 2013 Financial Results
For the three months ended March 31, 2013, Palatin reported a net loss of $4.0 million, or $(0.04) per basic and diluted share, compared to a net loss of $6.0 million, or $(0.17) per basic and diluted share, for the same period in 2012. 

The decrease in net loss for the quarter ended March 31, 2013, compared to the same period last fiscal year, is attributable to a decrease in operating expenses primarily related to Palatin's Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for the treatment of FSD. 

Revenue
Palatin did not recognize any revenues for the quarter ended March 31, 2013, compared to $23,996 for the quarter ended March 31, 2012.  Revenue consists of contract revenue under our collaboration agreement with AstraZeneca.

Costs and Expenses
Total operating expenses for the quarter ended March 31, 2013 were $4.0 million compared to $6.1 million for the comparable quarter of 2012.  The decrease in operating expenses for the quarter was primarily due to Palatin's Phase 2B clinical trial with bremelanotide for FSD and secondarily as a result of closing our research laboratory operations in connection with the lease expiration of the laboratory facilities in July 2012.

Cash Position
As of March 31, 2013, Palatin had cash and cash equivalents of $23.5 million, $6.0 million in short term investments and current liabilities of $2.7 million.  Cash and cash equivalents as of June 30, 2012 were $3.8 million with current liabilities of $3.5 million. 

Palatin believes that its existing capital resources will be adequate to fund its currently planned opera
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Palatin Technologies, Inc. To Report Fiscal Year 2013 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2013
2. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-Specific Peptides for Sexual Dysfunction
3. Palatin Technologies To Present At The 25th Annual ROTH Conference
4. Palatin Technologies, Inc. To Present At The Cowen & Company 33rd Annual Health Care Conference
5. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
6. Palatin Technologies, Inc. To Report Fiscal Year 2013 Second Quarter Results; Teleconference and Webcast to be held on February 14, 2013
7. Palatin Technologies, Inc. to Present at 15th Annual BIO CEO & Investor Conference
8. Palatin Technologies, Inc. to Present at the 24th Annual Piper Jaffray Healthcare Conference
9. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on November 14, 2012
10. Palatin Technologies, Inc. To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
11. Palatin Technologies, Inc. To Report Fiscal Year 2013 First Quarter Results; Teleconference and Webcast to be held on November 14, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... (PRWEB) January 22, 2015 Protocol Networks ... The growing team of brand-neutral, independent consultants, Protocol Networks ... Rogers explained that over the years, his company has ... Moroso, Town of Plainfield, as well as others. With ...
(Date:1/22/2015)... January 22, 2015 Controlled Substance Compliance ... which helps companies check the legal requirements around using ... to China. , As their international operations expand ... adopting software solutions built as a result of the ...
(Date:1/22/2015)... , Jan. 22. 2015  Varian Medical Systems (NYSE: ... has been honored for its commitment to sustainability with inclusion ... Varian is the highest ranked healthcare equipment company among the ... during the World Economic Forum at Davos, Switzerland ...
(Date:12/24/2014)... NEW YORK , Dec. 24, 2014 ... patient care in critical areas, announced the closing of an ... warrants to purchase up to an aggregate 3,500,000 shares of ... and $.01 per warrant.  The warrants have a per share ...
Breaking Biology Technology:Protocol Networks Brings Independent Technology Consulting to the Constitution State 2Global Compliance Service for Controlled Substances to Expand to China 2Varian Honored Among World's 100 Most Sustainable Corporations 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3
... Healthcare and Intermountain Health Care (IHC) ... program that would accelerate the adoption of electronic health ... announced at the annual Healthcare Information and Management Systems ... hope to take the clinical knowledge that IHC has ...
... Madison, Wis. How does one visualize thought? , ... pipette much thinner than a human hair against ... a patch and identify the electric current flowing through individual ... as the patch-clamp method, and it allows a peek at ...
... Third Wave Technologies this week reported the best ... year in which it met or exceeded all of its stated ... and a net loss of $1.9 million for the year ended ... net loss of $8.1 million for 2003. , ,The company ...
Cached Biology Technology:GE and Intermountain want to streamline nationwide patient data 2Prairie Technologies works with UW engineer to visualize the brain 2Third Wave boosts numbers in latest report 2Third Wave boosts numbers in latest report 3Third Wave boosts numbers in latest report 4
(Date:12/24/2014)... YORK , Dec. 23, 2014  Since its launch in December ... people to eliminate the pain of trying to remember their ... own biometrics fused to their smartphones. To assist people who ... , the company that created 1U and focuses on redefining ...
(Date:12/19/2014)... 18, 2014 Research and Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ... 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - ... http://photos.prnewswire.com/prnh/20130307/600769 Following the ... fingerprint reading feature with the iPhone 5S. It is ...
(Date:12/17/2014)... 15, 2014 Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ... Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology ... http://photos.prnewswire.com/prnh/20130307/600769 Based on a ... introduces for the first time a fingerprint sensor in ...
Breaking Biology News(10 mins):1U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2
... , , , , , , ... AUDIO: James Perfield discusses how the oil is similar to many vegetable oils currently on the market. , ... , , , , , , ... , , , , , COLUMBIA, Mo. Scientists have known for years that belly fat leads to ...
... BETHESDA, Md., March 24, 2011 We all know the adage: ... way. Now researchers in London are reporting that might also be ... The team at the Kennedy Institute of Rheumatology at Imperial ... a protein generated when the body is under stress, such as ...
... closer to making renewable petroleum fuels using bacteria, sunlight and ... Department of Energy grant. Graduate student Janice Frias, who ... figuring out how to use a protein to transform fatty ... cracked to make hydrocarbon fuels. The university is filing patents ...
Cached Biology News:Plant oil may hold key to reducing obesity-related medical issues, MU researcher finds 2Plant oil may hold key to reducing obesity-related medical issues, MU researcher finds 3Molecular muscle: Small parts of a big protein play key roles in building tissues 2Molecular muscle: Small parts of a big protein play key roles in building tissues 3U of M researchers close in on technology for making renewable petroleum 2
Na+/H+ exchanger, isoform NHE1....
Anti-Potassium Channel EAG-1 Immunogen: Synthetic peptide from the C-terminus of rat Kv10.1 (Accession Q63472). The immunogen sequence is identical in mouse and 14/16 residues identical in human...
Mouse monoclonal [DAPK-55] to DAP Kinase 1 ( Abpromise for all tested applications). entrezGeneID: 1612 SwissProtID: P53355...
IgG2b, k APC clone A95-1, Isotype Rat IgG2b, kappa, 0.1 mg ....
Biology Products: